Fig. 2: SARS-CoV-2-specific plasma IgG and IgA avidity in Group S and M. | Communications Biology

Fig. 2: SARS-CoV-2-specific plasma IgG and IgA avidity in Group S and M.

From: Anti-SARS-CoV-2 antibodies from severe COVID-19 individuals or S2 immunizations do not worsen disease in hamsters

Fig. 2

Antigen-specific IgG and IgA avidity (left to right) was evaluated in individuals with detectable antibodies specific against (A) RBD, (B) S2, and (C) Nucleocapsid. The number of patients with detectable antibodies in each category is indicated below each group. Comparison of (D) IgG or (E) IgA antibody avidity among antigens within each group (Group M on the left, Group S on the right). Differences between Group S and M were analyzed using Mann-Whitney U test and among antigens with Kruskal Wallis test corrected for false discovery rate (FDR). Mean with standard deviation is shown.

Back to article page